Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) AmyloidosisJanuary 20, 2021BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)July 17, 2023Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detectionMay 3, 2023 Previous postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosisNext post2026 Winter Newsletter
